Patent ID: 9295719
Filing Date: 2016-03-29
CPC Classification: A61K,A61P,C07K

Claim Text:
1. A method for treating a patient suffering from an amyloid disease or a tauopathy comprising administering to the patient a therapeutically effective amount of a polymerized form of an immunogenic modified Aβ peptide, which peptide contains Lysine substitutions in amino acid positions corresponding to amino acids 18 and 19 of Aβ1-42, which polymerized form is soluble, non-fibrillogenic, has molecular weight less than 100 kDa, has the property of eliciting antibodies directed against the abnormal conformation of Aβ in amyloid plaques and/or in soluble and semi-soluble Aβ oligomers, and is produced using controlled polymerization of peptide monomers with glutaraldehyde.